Shares of Laboratory Corp. of America Holdings (NYSE:LH) have been given a consensus rating of “Buy” by the twenty ratings firms that are currently covering the company. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $143.08.

A number of research firms have issued reports on LH. Canaccord Genuity set a $140.00 target price on shares of Laboratory Corp. of America Holdings and gave the company a “buy” rating in a report on Sunday, October 30th. Zacks Investment Research lowered shares of Laboratory Corp. of America Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, October 25th. Gabelli began coverage on shares of Laboratory Corp. of America Holdings in a report on Tuesday, October 25th. They issued a “buy” rating and a $180.00 target price on the stock. Mizuho upped their target price on shares of Laboratory Corp. of America Holdings from $132.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, September 15th. Finally, Citigroup Inc. began coverage on shares of Laboratory Corp. of America Holdings in a report on Friday, September 9th. They issued a “neutral” rating and a $156.00 target price on the stock. They noted that the move was a valuation call.

A number of hedge funds have recently modified their holdings of the stock. Canada Pension Plan Investment Board increased its stake in Laboratory Corp. of America Holdings by 16.2% in the first quarter. Canada Pension Plan Investment Board now owns 2,112 shares of the company’s stock worth $247,000 after buying an additional 295 shares during the last quarter. Wellington Management Group LLP increased its stake in Laboratory Corp. of America Holdings by 6.6% in the first quarter. Wellington Management Group LLP now owns 145,405 shares of the company’s stock worth $17,031,000 after buying an additional 8,947 shares during the last quarter. HBK Investments L P bought a new stake in Laboratory Corp. of America Holdings during the first quarter worth $395,000. Renaissance Technologies LLC increased its stake in Laboratory Corp. of America Holdings by 139.8% in the first quarter. Renaissance Technologies LLC now owns 281,805 shares of the company’s stock worth $33,008,000 after buying an additional 164,300 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in Laboratory Corp. of America Holdings by 130.2% in the first quarter. Nuveen Asset Management LLC now owns 13,625 shares of the company’s stock worth $1,596,000 after buying an additional 7,707 shares during the last quarter. 91.47% of the stock is owned by institutional investors.

Laboratory Corp. of America Holdings (NYSE:LH) opened at 126.00 on Tuesday. Laboratory Corp. of America Holdings has a one year low of $97.79 and a one year high of $141.32. The company has a 50 day moving average of $132.66 and a 200-day moving average of $132.78. The firm has a market cap of $12.98 billion, a PE ratio of 19.98 and a beta of 0.96.

Laboratory Corp. of America Holdings (NYSE:LH) last released its earnings results on Wednesday, October 26th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.29 by $0.04. The firm earned $2.40 billion during the quarter, compared to analysts’ expectations of $2.38 billion. Laboratory Corp. of America Holdings had a net margin of 6.85% and a return on equity of 16.97%. Laboratory Corp. of America Holdings’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $2.07 earnings per share. On average, equities research analysts predict that Laboratory Corp. of America Holdings will post $8.79 earnings per share for the current year.

About Laboratory Corp. of America Holdings

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Receive News & Stock Ratings for Laboratory Corp. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America Holdings and related stocks with our FREE daily email newsletter.